Effects of Atorvastatin on Negative Sign in Chronic Schizophrenia: a Double Blind Clinical Trial (Q36358431)

13 August 2017

Effects of Atorvastatin on Negative Sign in Chronic Schizophrenia: a Double Blind Clinical Trial (English)

1 reference

13 August 2017

0 references

chronic schizophrenia

1 reference

Mehdi Sayyah

1

1 reference

13 August 2017

Hatam Boostani

series ordinal

2

1 reference

13 August 2017

Mitra Ashrafpoori

series ordinal

3

1 reference

13 August 2017

Siroos Pakseresht

series ordinal

4

1 reference

13 August 2017

1 January 2015

1 reference

13 August 2017

6

1 reference

Iranian journal of pharmaceutical research

inferred from page(s)

published in

1 reference

13 August 2017

14

1 reference

13 August 2017

4

1 reference

13 August 2017

1269-1274

1 reference

A Double-Blind, Placebo-Controlled Study of the Aqueous Extract of Echium amoenum for Patients with General Anxiety Disorder

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673957

L-arginine and nitric oxide in CNS function and neurodegenerative diseases.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673957

The many faces of nitric oxide in schizophrenia. A review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673957

A separate disease within the syndrome of schizophrenia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673957

Neuroprotective properties of statins in cerebral ischemia and stroke

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673957

Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673957

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673957

Nitric oxide as a neurotransmitter in peripheral nerves: nature of transmitter and mechanism of transmission

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673957

Negative symptoms in schizophrenia. Definition and reliability

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673957

The positive and negative syndrome scale (PANSS) for schizophrenia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673957

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673957

Evaluation of Lipid-based Drug Delivery System (Phytosolve) on Oral Bioavailability of Dibudipine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673957

Performance evaluation of a novel potentiometric membrane sensor for determination of atorvastatin in pharmaceutical preparations

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673957

The impact of non-adherence to medication in patients with schizophrenia on health, social care and societal costs. Analysis of the QUATRO study.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673957

Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4673957

HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?

22 September 2018

1 reference

12 December 2020

Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study

1 reference

12 December 2020

Schizophrenia: the fundamental questions

1 reference

12 December 2020

Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes

1 reference

12 December 2020

Identifiers

1 reference

13 August 2017

1 reference